Autologous platelet transfusion in alloimmunized patients with acute leukemia

Ann Hematol. 1995 Oct;71(4):169-73. doi: 10.1007/BF01910313.

Abstract

Seventy-eight transfusions of autologous platelets were given to eight alloimmunized patients receiving curative chemotherapy for acute leukemia. Platelets were collected at regeneration of hematopoiesis after a chemotherapy cycle, cryopreserved with 5% dimethylsulfoxide in liquid nitrogen, and retransfused during bone marrow aplasia following the next treatment cycle. The in vitro platelet recovery after freezing, thawing, and washing was 85 +/- 4%. The in vivo corrected count increment 1 h after autologous platelet transfusions was 11 +/- 5 x 10(9)/l. With the exception of moderate urticaria and slight nausea each after one transfusion, no immediate or chronic side effects occurred. The bleeding time was shortened and hemorrhage during bone marrow aplasia was prevented in all alloimmunized patients by autologous platelet transfusions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Adolescent
  • Adult
  • Antilymphocyte Serum / blood
  • Blood Preservation
  • Blood Transfusion, Autologous
  • Cryopreservation
  • Female
  • Humans
  • Isoantigens / immunology*
  • Leukemia / drug therapy
  • Leukemia / immunology
  • Leukemia / therapy*
  • Leukemia, Monocytic, Acute / drug therapy
  • Leukemia, Monocytic, Acute / immunology
  • Leukemia, Monocytic, Acute / therapy
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / immunology
  • Leukemia, Myeloid, Acute / therapy
  • Leukemia, Myelomonocytic, Acute / drug therapy
  • Leukemia, Myelomonocytic, Acute / immunology
  • Leukemia, Myelomonocytic, Acute / therapy
  • Male
  • Middle Aged
  • Platelet Transfusion*
  • Prospective Studies
  • Recurrence
  • Remission Induction

Substances

  • Antilymphocyte Serum
  • Isoantigens